Binding of Human Urokinase-Type Plasminogen Activator to Its Receptor

Residues Involved in Species Specificity and Binding

From the Gaubius Laboratory, TNO-PG, Leiden, the Netherlands (P.H.A.Q., J.M.G., M.L., A.H.F.B., V.W.M. van H., J.H.V.); the Department of Pathology, Centre Medical Universitaire, Geneva, Switzerland (M.-C.B., D.B.); and the Institute for Cardiovascular Research, Free University Amsterdam, Amsterdam, the Netherlands (V.W.M. van H.).

Correspondence to Dr P.H.A. Quax, Gaubius Laboratory, TNO-PG, PO Box 2215, 2301 CE Leiden, the Netherlands. E-mail PHA.Quax{at}pg.tno.nl

Abstract—Urokinase-type plasminogen activator (UPA), particularly when bound to its receptor (UPAR), is thought to play a major role in local proteolytic processes, thus facilitating cell migration as may occur during angiogenesis, neointima and atherosclerotic plaque formation, and tumor cell invasion. To facilitate understanding of the need and function of the UPA/UPAR interaction in cell migration and vascular remodeling, we changed several amino acid residues in UPA so as to interfere with its interaction with its receptor. The receptor-binding domain of UPA has been localized to a region in the growth factor domain between residues 20 and 32. Since the binding of UPA to UPAR appears to be species specific, we used the differences in amino acid sequences in the growth factor domain of UPA between various species to construct a human UPA variant that does not bind to the human UPAR. We substituted Asn22 for its mouse equivalent Tyr by site-directed mutagenesis. This mutant UPA had similar plasminogen activator characteristics as wild-type UPA, including its specific activity and interaction with plasminogen activator inhibitor-1. However, no UPA/UPAR complexes could be observed in cross-linking experiments using DFP-treated ¹²⁵I-labeled mutant UPA and lysates of various cells, including U937 histiocytic lymphoma cells, phorbol myristate acetate—treated human ECs, and mouse LB6 cells transfected with human UPAR cDNA. In direct binding experiments, DFP-treated¹²⁵I-labeled mutant UPA could not bind to phorbol myristate acetate–treated ECs, whereas wild-type UPA did bind. Furthermore, a 25-fold excess of wild-type UPA completely prevented the binding of DFP-treated ¹²⁵I-labeled wild-type UPA to the human receptor on transfected LB6 cells, whereas an equal amount of mutant UPA had only a very small effect. In ligand blotting assays, very weak binding of mutant UPA to human UPAR could be observed. Changing Asn22 into the other amino acid residues alanine or glutamine had no effect on binding to UPAR on human ECs. The functional integrity of the growth factor domain in the non–receptor binding Asn22Tyr mutant is suggested by the fact that binding of this mutant to a murine UPAR can be restored after additional mutations in the growth factor domain, Asn27,His29,Trp30 to Arg27,Arg29,Arg30. We conclude that Asn22 and Asn27,His29,Trp30 in human UPA are key determinants in the species-specific binding of the enzyme to its receptor and that changing Asn22 into Tyr results in a UPA mutant with strongly reduced binding to UPAR.

Key Words: urokinase-type plasminogen activator • urokinase-type plasminogen activator receptor • site-directed mutagenesis

This article has been cited by other articles:

				L. Yang, X.-H. Peng, Y. A. Wang, X. Wang, Z. Cao, C. Ni, P. Karna, X. Zhang, W. C. Wood, X. Gao, et al. Receptor-Targeted Nanoparticles for In vivo Imaging of Breast Cancer Clin. Cancer Res., July 15, 2009; 15(14): 4722 - 4732. [Abstract] [Full Text] [PDF]

				Y. Jing, C. Tong, J. Zhang, T. Nakamura, I. Iankov, S. J. Russell, and J. R. Merchan Tumor and Vascular Targeting of a Novel Oncolytic Measles Virus Retargeted against the Urokinase Receptor Cancer Res., February 15, 2009; 69(4): 1459 - 1468. [Abstract] [Full Text] [PDF]

				Z.-B. Li, G. Niu, H. Wang, L. He, L. Yang, M. Ploug, and X. Chen Imaging of Urokinase-Type Plasminogen Activator Receptor Expression Using a 64Cu-Labeled Linear Peptide Antagonist by microPET Clin. Cancer Res., August 1, 2008; 14(15): 4758 - 4766. [Abstract] [Full Text] [PDF]

				X.-Q. Wang, K. Bdeir, S. Yarovoi, D. B. Cines, W. Fang, and E. Abraham Involvement of the Urokinase Kringle Domain in Lipopolysaccharide-Induced Acute Lung Injury J. Immunol., October 15, 2006; 177(8): 5550 - 5557. [Abstract] [Full Text] [PDF]

				J. R. Merchan, J. Tang, G. Hu, Y. Lin, W. Mutter, C. Tong, S. A. Karumanchi, S. J. Russell, and V. P. Sukhatme Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst, June 7, 2006; 98(11): 756 - 764. [Abstract] [Full Text] [PDF]

				Q. Huai, A. P. Mazar, A. Kuo, G. C. Parry, D. E. Shaw, J. Callahan, Y. Li, C. Yuan, C. Bian, L. Chen, et al. Structure of Human Urokinase Plasminogen Activator in Complex with Its Receptor Science, February 3, 2006; 311(5761): 656 - 659. [Abstract] [Full Text] [PDF]

				S.-H. Kwak, S. Mitra, K. Bdeir, D. Strassheim, J. S. Park, J. Y. Kim, S. Idell, D. Cines, and E. Abraham The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins J. Leukoc. Biol., October 1, 2005; 78(4): 937 - 945. [Abstract] [Full Text] [PDF]

				L. Holterman, R. Vogels, R. van der Vlugt, M. Sieuwerts, J. Grimbergen, J. Kaspers, E. Geelen, E. van der Helm, A. Lemckert, G. Gillissen, et al. Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5 J. Virol., December 1, 2004; 78(23): 13207 - 13215. [Abstract] [Full Text] [PDF]

				K. Bdeir, A. Kuo, B. S. Sachais, A. H. Rux, Y. Bdeir, A. Mazar, A. A.-R. Higazi, and D. B. Cines The kringle stabilizes urokinase binding to the urokinase receptor Blood, November 15, 2003; 102(10): 3600 - 3608. [Abstract] [Full Text] [PDF]

				E. Abraham, M. R. Gyetko, K. Kuhn, J. Arcaroli, D. Strassheim, J. S. Park, S. Shetty, and S. Idell Urokinase-Type Plasminogen Activator Potentiates Lipopolysaccharide-Induced Neutrophil Activation J. Immunol., June 1, 2003; 170(11): 5644 - 5651. [Abstract] [Full Text] [PDF]

				M.L.M. Lamfers, J.M. Grimbergen, M.C. Aalders, M.J. Havenga, M.R. de Vries, L.G.M. Huisman, V.W.M. van Hinsbergh, and P.H.A. Quax Gene Transfer of the Urokinase-Type Plasminogen Activator Receptor-Targeted Matrix Metalloproteinase Inhibitor TIMP-1.ATF Suppresses Neointima Formation More Efficiently Than Tissue Inhibitor of Metalloproteinase-1 Circ. Res., November 15, 2002; 91(10): 945 - 952. [Abstract] [Full Text] [PDF]

				D. A. Vallera, C. Li, N. Jin, A. Panoskaltsis-Mortari, and W. A. Hall Targeting Urokinase-Type Plasminogen Activator Receptor on Human Glioblastoma Tumors With Diphtheria Toxin Fusion Protein DTAT J Natl Cancer Inst, April 17, 2002; 94(8): 597 - 606. [Abstract] [Full Text] [PDF]

				M. J. E. Havenga, A. A. C. Lemckert, J. M. Grimbergen, R. Vogels, L. G. M. Huisman, D. Valerio, A. Bout, and P. H. A. Quax Improved Adenovirus Vectors for Infection of Cardiovascular Tissues J. Virol., April 1, 2001; 75(7): 3335 - 3342. [Abstract] [Full Text]

				L. Kjoller and A. Hall Rac Mediates Cytoskeletal Rearrangements and Increased Cell Motility Induced by Urokinase-Type Plasminogen Activator Receptor Binding to Vitronectin J. Cell Biol., March 19, 2001; 152(6): 1145 - 1158. [Abstract] [Full Text] [PDF]

				P. H. A. Quax, M. L. M. Lamfers, J. H. P. Lardenoye, J. M. Grimbergen, M. R. de Vries, J. Slomp, M. C. de Ruiter, M. M. Kockx, J. H. Verheijen, and V. W. M. van Hinsbergh Adenoviral Expression of a Urokinase Receptor-Targeted Protease Inhibitor Inhibits Neointima Formation in Murine and Human Blood Vessels Circulation, January 30, 2001; 103(4): 562 - 569. [Abstract] [Full Text] [PDF]